Results 251 to 260 of about 212,746 (279)

CDKN2A/p16 in ependymomas

Journal of Neuro-Oncology, 2001
Sixteen cases of ependymoma were studied for CDKN2A/p16 inactivation by immunohistochemistry using a p16 monoclonal antibody, by homozygous deletion (HD) assay and 5'CpG promoter methylation assay (methylation-specific PCR). Three out of 16 cases were p16 immuno-negative: two corresponded to grade II ependymomas and one to grade III.
BORTOLOTTO S, CHIADO'-PIAT, Loredana, CAVALLA P, BOSONE I, MAURO, Alessandro, SCHIFFER D.   +5 more
openaire   +3 more sources

Treatment response in the neck: p16+ versus p16− oropharyngeal cancer

Journal of Medical Imaging and Radiation Oncology, 2013
AbstractIntroductionTo compare nodal response rates following chemoradiotherapy in patients with p16+ and p16− oropharyngeal squamous cell carcinoma (OPSCC).MethodsPatients with node‐positive OPSCC treated at Peter MacCallum Cancer Centre on the published phase I–III tirapazamine trials were identified.
Daisy, Mak, Rodney J, Hicks, Danny, Rischin, Ben, Solomon, Lester, Peters, Mathias, Bressel, Richard J, Young, June, Corry   +7 more
openaire   +2 more sources

CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.

International Journal of Oncology, 1998
CDKN2/p16 inactivation is the most frequent alteration in the molecular regulation of G1-S transition. CDKN2/p16 homozygous deletions was studied in paraffin-embedded sections of 45 astrocytic tumours by multiplex PCR. Immunohistochemistry for p16 and proliferation marker Ki-67 MIB-1 was performed in adjacent sections; their labelling index (LI) have ...
PIVA, Roberto, CAVALLA P., BORTOLOTTO S., CORDERA S., GROSSO R., RICHIARDI P., DUTTO A., SCHIFFER D.   +7 more
openaire   +3 more sources

P16

Surgery for Obesity and Related Diseases, 2006
Robert A. Frankel, Candyce Kaaiai, Carlos Weber   +2 more
  +4 more sources

P16

Journal of Surgical Research, 2007
K. Brasel, J. Kiely, H. Yang, C. Guse, J.A. Weigelt   +4 more
  +4 more sources

?????????????? ???????????????????? ?????????? p16 ink4a ?? ?????????????? ?????????????? ?????????????????? ???????????????? ?????? ?????????????????? ?????????? ??????????

2018
???????? ????????????: ???????????????? ?????????????? ?????????????????????????????? p16INK4a ?? ?????????????????? ?? ?????????????????????? ???????????????????? ?????????? ?????????? (????) ?? ?????????????????????? ???? ?????????????????????????? (???? ???????????? ???????????????????????? ???????????? ?????????????? ??? ??????) ????????????????????
openaire   +2 more sources

Kolofon P16

Peripeti
Peripeti © Peripeti og forfatterne Temaredaktion Siemke Bohnisch, Rikke Giirgens Gjærum, Thomas Rosendal Nielsen og Erik Exe Christoffersen. Redaktion Janicke Branth, Erik Exe Christoffersen (ansv.), Michael Eigtved, Solveig Gade, Louise Ejgod Hansen, Falk Heinrich, Birgitte Hesselaa, Kjertsi Hustvedt, Thomas D. Kragebæk, Jens Christian Lauenstein
openaire   +1 more source

p16 Tumor Suppressor

2001
p16, a protein named for its migration rate on denaturing gels, is a member of a class of functionally similar proteins called cyclin-dependent kinase inhibitors (CDKI). p16 and its relatives bind to CDKs and inhibit their kinase activity. Because cyclins and CDKs form the core of the cell cycle apparatus, p16 is positioned to directly regulate some of
Alexander Kamb, Ken McCormack
openaire   +1 more source

p16

Free Radical Biology and Medicine, 2016
  +4 more sources